SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area

Dianna L Ng; Gregory M Goldgof; Brian R Shy; Andrew G Levine; Joanna Balcerek; Sagar P Bapat; John Prostko; Mary Rodgers; Kelly Coller; Sandy Pearce; Sergej Franz; Li Du; Mars Stone; Satish K Pillai; Alicia Sotomayor-Gonzalez; Venice Servellita; Claudia Sanchez San Martin; Andrea Granados; Dustin R Glasner; Lucy M Han; Kent Truong; Naomi Akagi; David N Nguyen; Neil M Neumann; Daniel Qazi; Elaine Hsu; Wei Gu; Yale A Santos; Brian Custer; Valerie Green; Phillip Williamson; Nancy K Hills; Chuanyi M Lu; Jeffrey D Whitman; Susan Stramer; Candace Wang; Kevin Reyes; Jill M C Hakim; Kirk Sujishi; Fariba Alazzeh; Lori Pham; Ching-Ying Oon; Steve Miller; Theodore Kurtz; John Hackett Jr; Graham Simmons; Michael P Busch; Charles Y Chiu

doi:10.1101/2020.05.19.20107482

SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area

medRxiv [Preprint]. 2020 May 25:2020.05.19.20107482. doi: 10.1101/2020.05.19.20107482.

Authors

Dianna L Ng^{1

2}, Gregory M Goldgof¹, Brian R Shy¹, Andrew G Levine¹, Joanna Balcerek¹, Sagar P Bapat¹, John Prostko³, Mary Rodgers³, Kelly Coller³, Sandy Pearce³, Sergej Franz⁴, Li Du⁴, Mars Stone^{1

4}, Satish K Pillai⁴, Alicia Sotomayor-Gonzalez^{1

5}, Venice Servellita^{1

5}, Claudia Sanchez San Martin^{1

5}, Andrea Granados^{1

5}, Dustin R Glasner^{1

5}, Lucy M Han^{1

2}, Kent Truong^{1

2}, Naomi Akagi^{1

2}, David N Nguyen⁶, Neil M Neumann², Daniel Qazi², Elaine Hsu¹, Wei Gu¹, Yale A Santos^{1

5}, Brian Custer⁴, Valerie Green⁷, Phillip Williamson⁷, Nancy K Hills^{8

9}, Chuanyi M Lu^{1

10}, Jeffrey D Whitman¹, Susan Stramer¹¹, Candace Wang^{1

5}, Kevin Reyes^{1

5}, Jill M C Hakim¹², Kirk Sujishi¹, Fariba Alazzeh¹, Lori Pham¹, Ching-Ying Oon¹, Steve Miller^{1

5}, Theodore Kurtz¹, John Hackett Jr³, Graham Simmons^{1

4}, Michael P Busch^{1

4}, Charles Y Chiu^{1

5

6}

Affiliations

¹ Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
² Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.
³ Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, USA.
⁴ Vitalant Research Institute, San Francisco, CA, USA.
⁵ UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
⁶ Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, San Francisco, CA, USA.
⁷ Creative Testing Solutions, Tempe, AZ, USA.
⁸ Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
⁹ Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
¹⁰ Lab Medicine Service, San Francisco VA Healthcare System.
¹¹ American Red Cross, Gaithersburg, MD, USA.
¹² Department of Medicine at ZSFG, the Division of HIV, ID & Global Medicine.

Abstract

We report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seropositivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors. We additionally describe the longitudinal dynamics of immunoglobulin-G, immunoglobulin-M, and in vitro neutralizing antibody titers in COVID-19 patients. Neutralizing antibodies rise in tandem with immunoglobulin levels following symptom onset, exhibiting median time to seroconversion within one day of each other, and there is >93% positive percent agreement between detection of immunoglobulin-G and neutralizing titers.

Publication types

Preprint

Abstract

Publication types

Grants and funding